ArticleBMC cardiovascular disorders2025
Left atrial energy loss as a novel predictor of mortality and cardiovascular events in chronic kidney disease patients with preserved ejection fraction.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease (CKD) have an increased risk of cardiovascular adverse events and abnormal intracardiac blood flow, which are commonly underestimated when evaluated by traditional echocardiographic parameters. Energy loss (EL), a novel Vector Flow Mapping (VFM) -based parameter, enables early hemodynamic assessment of cardiac dysfunction. This study sought to explore whether EL of left atrial has prognostic value for cardiovascular risk in CKD patients with preserved ejection fraction.
methodsA total of 137 prospectively recruited patients with CKD in stages 3-5 and normal left ventricular ejection fraction (LVEF) (67% male, mean age 50.74 ± 13.23 years) underwent measurement of left atrial energy loss (LAEL) within three cardiac cycles, using VFM technology. Participants were followed up for an average of 5.11 ± 1.50 years, with the primary endpoints being all-cause mortality and major adverse cardiovascular events (MACE).
resultsMajor endpoint events occurred in 46 cases (34%). Mean LAEL (M-LAEL) was significantly higher in patients with adverse events than in those without. M-LAEL (hazard ratio [HR]: 2.84, 95% confidence interval [CI]: 1.97-4.09) was identified as an independent predictor of the major endpoint. An increase in M-LAEL (≥ 2.05 × 10
conclusionsM-LAEL demonstrated robust predictive power for overall mortality and MACE in CKD, highlighting its potential for early cardiovascular risk stratification and timely intervention in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.